Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the ...

The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding ...

Treating PAH patient-derived blood vessel cells with calcitriol reduced vitamin D receptor deficiency and suppressed their ...

Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...

Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...

Cardiopulmonary exercise testing allows for a comprehensive assessment of the mechanism of exercise limitation in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

The Mini Nutritional Assessment was viable for assessing nutritional status and predicting mortality outcomes in patients ...

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg ...

Unfortunately, clinical symptoms of PAH are unspecific and are late manifestations of the disease. [3] As in this case, dyspnea on exertion is often the leading clinical symptom; however, dyspnea ...